Be careful with highly anticipated events that are expecting positive data! Today, I talk about Zogenix and their expected Phase 3 results. They previously showed good data in their Phase 3 Study 1 trial but this time with patients taking Stiripentol. Try not to get caught playing events that are priced in like FDA approval of GW’s Epidiolex.
Follow me @matthewlepoire
*This is not investment advice*